Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Measurement of Blood Pressure01:17

Measurement of Blood Pressure

3.5K
Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
3.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

397
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
397
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

367
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
367
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

533
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
533

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study.

Research and practice in thrombosis and haemostasis·2026
Same author

Fibrin-bound thrombin determines clot structure and blood thrombogenicity in normofibrinogenemia and dysfibrinogenemia.

Haematologica·2026
Same author

Thrombin generation and thrombin dynamics are associated with recurrent venous thromboembolism after anticoagulation withdrawal.

Journal of thrombosis and haemostasis : JTH·2026
Same author

The use of light transmission aggregometry for monitoring platelet transfusion response in a small case cohort of Glanzmann thrombasthenia patients: a hypothesis-generating study.

Platelets·2026
Same author

HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease.

Blood advances·2026
Same author

Beyond Arg39: new insights into antiphospholipid antibodies.

Blood·2025

Related Experiment Video

Updated: Feb 23, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.6K

The Lupus Anticoagulant Paradox.

Jessica E Molhoek1, Philip G de Groot1, Rolf T Urbanus1

  • 1Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands.

Seminars in Thrombosis and Hemostasis
|September 13, 2017
PubMed
Summary

Lupus anticoagulant (LA) antibodies prolong clotting time but paradoxically increase thrombosis risk in antiphospholipid syndrome. This review explores LA antibodies, their clinical significance, and the thrombosis paradox.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Related Experiment Videos

Last Updated: Feb 23, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.6K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Area of Science:

  • Hematology
  • Immunology
  • Obstetrics

Background:

  • Lupus anticoagulant (LA) is a key marker in antiphospholipid syndrome (APS).
  • LA antibodies paradoxically prolong clotting time while increasing thrombotic risk.
  • Understanding the LA antibody-thrombosis link is crucial for patient management.

Purpose of the Study:

  • To review antibodies associated with LA activity.
  • To discuss the clinical importance of these antibodies.
  • To elucidate the mechanism linking LA to thrombosis rather than bleeding.

Main Methods:

  • Literature review of clinical studies on LA antibodies.
  • Analysis of antibody-associated LA activity.
  • Exploration of pathophysiological mechanisms.

Main Results:

  • Various antibodies contribute to LA activity.
  • LA is a significant predictor of thrombosis and pregnancy morbidity in APS.
  • The prothrombotic mechanism remains incompletely understood but involves phospholipid interactions.

Conclusions:

  • LA antibodies represent a complex diagnostic and prognostic challenge in APS.
  • Further research is needed to fully clarify the prothrombotic pathways.
  • Accurate identification and understanding of LA antibodies are vital for improving APS patient outcomes.